Tumor Mutational Burden as a Potential Predictive Biomarker of Response to PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer

被引：0
|
作者：
Kim, H. [1 ]
Kwon, H. J. K. [1 ]
Kim, E. S. K. [1 ]
Han, Y. B. [2 ]
Lee, J. [2 ,4 ]
Kim, S. H. [3 ]
Kim, Y. J. [2 ]
Lee, J. [2 ,4 ]
Chung, J. [1 ]
机构：
[1] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Pathol, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Seongnam, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
tumor mutational burden; predictive biomarker; Non-Small Cell Lung Cancer;
D O I：
10.1016/j.jtho.2019.08.975
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-72
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 50 条
  • [1] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
  • [2] Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
    Di Huang
    Fan Zhang
    Haitao Tao
    Sujie Zhang
    Junxun Ma
    Jinliang Wang
    Zhefeng Liu
    Pengfei Cui
    Shixue Chen
    Ziwei Huang
    Zhaozhen Wu
    Lei Zhao
    Yi Hu
    [J]. Targeted Oncology, 2020, 15 : 93 - 100
  • [3] Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
    Huang, Di
    Zhang, Fan
    Tao, Haitao
    Zhang, Sujie
    Ma, Junxun
    Wang, Jinliang
    Liu, Zhefeng
    Cui, Pengfei
    Chen, Shixue
    Huang, Ziwei
    Wu, Zhaozhen
    Zhao, Lei
    Hu, Yi
    [J]. TARGETED ONCOLOGY, 2020, 15 (01) : 93 - 100
  • [4] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [5] Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade
    Si-Chong Han
    Gui-Zhen Wang
    Ya-Ning Yang
    Wen-Feng Fang
    Bei-Bei Sun
    Jian-Dong Zhang
    Hua-Qiang Zhou
    Li Zhang
    Yan Wang
    Guang-Biao Zhou
    [J]. Signal Transduction and Targeted Therapy, 8
  • [6] A Meta-Analysis of PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced Non-Small Cell Lung Cancer
    Man, J.
    Gebski, V.
    Mulvey, A.
    Hui, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2001 - S2002
  • [7] Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade
    Han, Si-Chong
    Wang, Gui-Zhen
    Yang, Ya-Ning
    Fang, Wen-Feng
    Sun, Bei-Bei
    Zhang, Jian-Dong
    Zhou, Hua-Qiang
    Zhang, Li
    Wang, Yan
    Zhou, Guang-Biao
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [8] Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
    Shien, Kazuhiko
    Papadimitrakopoulou, Vassiliki A.
    Wistuba, Ignacio I.
    [J]. LUNG CANCER, 2016, 99 : 79 - 87
  • [9] PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
    Bocanegra, Ana
    Fernandez-Hinojal, Gonzalo
    Zuazo-Ibarra, Miren
    Arasanz, Hugo
    Jesus Garcia-Granda, Maria
    Hernandez, Carlos
    Ibanez, Maria
    Hernandez-Marin, Berta
    Martinez-Aguillo, Maite
    Jose Lecumberri, Maria
    Fernandez de Lascoiti, Angela
    Teijeira, Lucia
    Morilla, Idoia
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07):
  • [10] Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
    Huang, Mu-Yang
    Jiang, Xiao-Ming
    Wang, Bing-Lin
    Sun, Yang
    Lu, Jin-Jian
    [J]. PHARMACOLOGY & THERAPEUTICS, 2021, 219
12345